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Abstract
Background: Polymorphisms in the MHC class 1-like gene known as HFE have been proposed as
genetic modifiers of neurodegenerative diseases that include neuroinflammation as part of the
disease process. Variants of HFE are relatively common in the general population and are most
commonly associated with iron overload, but can promote subclinical cellular iron loading even in
the absence of clinically identified disease. The effects of the variants as well as the resulting cellular
iron dyshomeostasis potentially impact a number of disease-associated pathways. We tested the
hypothesis that the two most common HFE variants, H63D and C282Y, would affect cellular
secretion of cytokines and trophic factors.
Methods: We screened a panel of cytokines and trophic factors using a multiplexed immunoassay
in human neuroblastoma SH-SY5Y cells expressing different variants of HFE. The influence of
cellular iron secretion on the potent chemokine monocyte chemoattractant protein-1 (MCP-1)
was assessed using ferric ammonium citrate and the iron chelator, desferroxamine. Additionally, an
antioxidant, Trolox, and an anti-inflammatory, minocycline, were tested for their effects on MCP-
1 secretion in the presence of HFE variants.
Results: Expression of the HFE variants altered the labile iron pool in SH-SY5Y cells. Of the panel
of cytokines and trophic factors analyzed, only the release of MCP-1 was affected by the HFE
variants. We further examined the relationship between iron and MCP-1 and found MCP-1
secretion tightly associated with intracellular iron status. A potential direct effect of HFE is
considered because, despite having similar levels of intracellular iron, the association between HFE
genotype and MCP-1 expression was different for the H63D and C282Y HFE variants. Moreover,
HFE genotype was a factor in the effect of minocycline, a multifaceted antibiotic used in treating a
number of neurologic conditions associated with inflammation, on MCP-1 secretion.
Conclusion:  Our results demonstrate that HFE polymorphisms influence the synthesis and
release of MCP-1. The mechanism of action involves cellular iron status but it appears there could
be additional influences such as ER stress. Finally, these data demonstrate a pharmacogenetic effect
of HFE polymorphisms on the ability of minocycline to inhibit MCP-1 secretion.
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Background
Iron accumulation in various brain regions is associated
with the pathogenesis of several neurodegenerative dis-
eases. The relationship between loss of brain iron home-
ostasis and the diseases appears to be generation of
oxidative stress and exacerbation of inflammatory
responses. The degree to which loss of iron homeostasis
contributes to cell dysfunction and loss is not clear. Cellu-
lar iron homeostasis involves the complex interaction of
numerous proteins, and genetic variants in genes encod-
ing these proteins may influence this process and hence
pathogenesis and disease progression. Polymorphisms in
the major histocompatibility complex class 1-like gene known
as HFE have been proposed as genetic modifiers of amyo-
trophic lateral sclerosis (ALS) [1], Alzheimer's disease
(AD) [2], Parkinson's disease (PD) [3], and stroke [4]. The
HFE protein is primarily thought to regulate transferrin-
mediated cellular iron intake through its interaction with
the transferrin receptor [5], but a recent study from our
laboratory suggests a potentially broader role in cell func-
tion [6]. The H63D HFE variant appears deficient in
reducing the affinity of the transferrin receptor for trans-
ferrin, while the C282Y HFE variant aggregates in the
endoplasmic reticulum [5,7]. These HFE variants are
thought to underlie the iron overload disorder known as
hemochromatosis, but appear to have low penetration
rates [8]. Nonetheless, there is little disagreement that
HFE variants impact iron status at the cellular level inde-
pendent of clinical disease [5-7,9].
Cellular iron dysregulation has the potential to indirectly
impact numerous disease-associated pathways. Our study
is focused on the link between cellular iron regulation and
secretion of soluble mediators of inflammatory reactions
[10,11]. Iron dysregulation in neuronal cells induces tox-
icity [12], potentially resulting in recruitment of inflam-
matory cells [13]. One factor proposed to contribute to
the relentless progression associated with many neurode-
generative diseases is the recruitment and activation of
microglia in the regions of neuronal death [14]. As medi-
ators of innate immunity in the central nervous system,
microglia respond to a variety of cytokines and chemok-
ines and in turn secrete a variety of inflammatory media-
tors and trophic factors which likely contribute to
neurodegenerative disease pathogenesis.
By influencing cellular iron homeostasis, we hypothesize
that HFE variants may differentially impact secretion of
cytokines and trophic factors, which may explain the asso-
ciation of these alleles with various diseases. In the current
study we determine the influence of HFE variants and iron
regulation on cellular secretion of factors relevant to neu-
rodegenerative disease and explore mechanisms underly-
ing these relationships.
Methods
Materials
SH-SY5Y human neuroblastoma cell lines and human
astrocytoma cell lines U251 and U138 MG, were obtained
from American Type Culture Collection (Manassas, VA).
Mouse microglial BV-2 cells were a kind gift of Dr. Steven
W. Levison (University of Medicine & Dentistry of New
Jersey). Cell culture reagents including DMEM/F12,
DMEM, penicillin/streptomycin, penicillin/streptomycin/
glutamine and Geneticin, as well as calcein-AM were pur-
chased from Invitrogen (Carlsbad, CA). Fetal bovine
serum was purchased from Gemini Bio-Products (West
Sacramento, CA). MTS reagent was purchased from
Promega (Chatsworth, CA). PCR primers for MCP-1 were
purchased from SuperArray (Frederick, MD). The DNeasy
Tissue kit and RNeasy Mini kit were purchased from Qia-
gen (Valencia, CA). The DC protein assay and the Bio-Plex
Human 27-plex panel of cytokines and growth factors
were obtained from Bio-Rad (Hercules, CA). Anti-Hsp70
and anti-Hsp90 antibodies were purchased from Stress-
gen (Ann Arbor, MI). All other reagents were purchased
from Sigma-Aldrich (St. Louis, MO).
Cell culture
As previously reported [1], we created stably-transfected
human neuroblastoma SH-SY5Y cell lines expressing
FLAG-tagged wildtype (Wt), H63D, and C282Y forms of
HFE. This cell line was chosen because it lacks endog-
enous HFE expression [1,6]. As a control, we also trans-
fected cells with vector alone. Transfected cells were
maintained in DMEM/F12 medium supplemented with
10% FBS, 1% penicillin/streptomycin/glutamine, 1× non-
essential amino acids, 1.8 g/L sodium bicarbonate, and
250 μg/mL Geneticin. Prior to use, cells were differenti-
ated for four to six days in 10 μM all-trans retinoic acid
and the genotype of each cell line was confirmed by
sequencing. Vector control cells were included in analyses
to control for phenotypic changes associated with the cell
transfection. The more direct control for the HFE poly-
morphisms, however, is the Wt HFE transfected cells,
because of the effect of Wt/Wt HFE on cellular iron status
that does not occur in the cells transfected with vector
alone which do not express HFE (Figure 1).
Astrocytoma cell lines were maintained in Dulbecco's
Modified Eagle's Medium supplemented with 10% fetal
bovine serum and 1% penicillin/streptomycin. BV-2 cells
were maintained in DMEM supplemented with 10% heat-
inactivated FBS and 1% penicillin/streptomycin. Cells
were generally used after seven to ten (maximum) pas-
sages.
HFE genotyping
Genomic DNA was extracted from astrocytoma cell lines
using the DNeasy Tissue kit according to the manufac-Journal of Neuroinflammation 2009, 6:6 http://www.jneuroinflammation.com/content/6/1/6
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turer's instructions. The PCR-amplified DNA samples
were digested by restriction enzymes to determine the
HFE genotype [15]. DNA (50 ng) was amplified by PCR
using the primers forward: 5'-ACA TGG TTA AGG CCT
GTT GC-3', and reverse: 5' CTT GCT GTG GTT GTG ATT
TTC C-3' for detection of the H63D allele, and primers for-
ward: 5' CAA GTG CCT CCT TTG GTG AAG GTG ACA
CAT-3', and reverse: 5' CTC AGG CAC TCC TCT CAA CC-
3' for the C282Y allele. The PCR reaction was performed
in a total volume of 50 μL containing 100 pmol of each
primer in a PTC-200 Peltier Thermal Cycler (MJ Research,
Woburn, MA). The PCR reaction was initiated at 95°C for
15 min, followed by 40 cycles of denaturation at 95°C for
45 s, annealing at 58°C for 45 s, and extension at 72°C for
1 min 30 s. A 294 bp product was obtained for the H63D
polymorphism. Following digestion with MboI, the 63D
allele gave restriction fragments of 237 and 57 bp, while
the H63 allele resulted in three fragments (138, 99 and 57
bp). For the C282Y polymorphism, the primers resulted
in a 343 bp product. Following digestion with RsaI, the
282Y allele resulted in products of 203, 111 and 29 bp,
whereas the C282 allele yielded restriction fragments of
203 and 140 bp. Polymorphisms were detected by restric-
tion fragment length analysis in 5% TBE polyacrylamide
gel.
Cell viability assays
Differentiated SH-SY5Y cell lines were grown in 96-well
plates until 70–80% confluent. Cells were treated with
various concentrations of desferroxamine (DFO), ferric
ammonium citrate (FAC), Trolox and minocycline. Cell
viability was assessed with the colorimetric agent MTS and
compared to untreated cells.
Western blotting
SH-SY5Y cells were grown as separate cultures until
approximately 80% confluent. Cells were lysed with a
RIPA buffer supplemented with 1% Triton X-100 and pro-
tease inhibitor cocktail. Forty micrograms total protein
was separated by electrophoresis in a 4–20% Criterion
polyacrylamide gel. Protein was then transferred to a
nitrocellulose membrane and blocked for 1 hr at room
temperature in TBS-T with 5% nonfat milk. Membranes
were then probed with anti-FLAG (1:2000), anti-Hsp70
(1:1000) and anti-Hsp90 (1:1000) primary antibodies in
TBS-T with 5% nonfat milk overnight at 4°C. HRP-conju-
gated secondary antibodies (1:5000) were then added in
5% nonfat milk for 1 hr at room temperature. Signals were
obtained by chemiluminescence and visualized by CCD
camera. Each blot shows results obtained from three inde-
pendent cell cultures.
Intracellular labile iron
Intracellular labile iron was determined in the SH-SY5Y
cells using the cell-permeable dye calcein-AM. Cells were
grown in 24-well plates to 80% confluency. Calcein-AM
was then added in medium at a final concentration of
0.25 μM and cells were incubated at 37°C for 30 minutes.
Cells were then washed three times in ice-cold Hanks' bal-
anced salt solution and lysed in 200 μL RIPA buffer plus
1% Triton X-100. The fluorescence of the lysate was meas-
ured and normalized to the protein content of the lysate,
Confirmation of cell transfection Figure 1
Confirmation of cell transfection. (A) A representative western blot is shown demonstrating FLAG-tagged HFE expres-
sion in transfected SH-SY5Y cells (B) Intracellular labile iron was determined in the differentiated SH-SY5Y cells using the cell-
permeable dye calcein-AM, as described in Methods. Fluorescence of calcein is quenched in the presence of iron, thus fluores-
cence is inversely proportional to labile iron levels. Intracellular labile iron levels were in the order C282Y > H63D = Vector > 
Wt. Results are reported here as the average ± SEM of three independent assays. * and *** indicate p < 0.05 and p < 0.001, 
respectively, compared to Wt.
FLAG-HFE
A B
vector Wt H63D C282YJournal of Neuroinflammation 2009, 6:6 http://www.jneuroinflammation.com/content/6/1/6
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determined by BioRad DC protein assay, after subtracting
a blank consisting of cells incubated with medium lacking
the dye.
Multiplex cytokine bead assay
We performed multiplex analysis on undiluted cell cul-
ture supernatants using the Bio-Plex Human 27-plex
panel of cytokines and growth factors listed in Table 1
(Bio-Rad; Hercules, CA). Briefly, cells were plated in 24-
well plates and grown to approximately 70% confluency.
Medium was then changed, and cells were incubated for
48 hrs. Cells were lysed in RIPA buffer after samples of
media were removed and analyzed by a multiplex anti-
body-based assay. Fifty μL of each sample or standard was
added in duplicate to a 96-well filter plate and mixed with
50 μL of antibody-conjugated beads for one hour at room
temperature. After one hour, wells were washed and 25 μL
of detection antibody was added to each well. After 30
minutes incubation, wells were washed and 50 μL of
streptavidin-PE was added to each well and incubated for
10 minutes. A final wash cycle was then completed and
125 μl of assay buffer was added to each well. The plate
was then analyzed using a Bio-Plex 200 workstation (Bio-
Rad). Analyte concentration was calculated based on the
respective standard curve for each cytokine.
Measurement of MCP-1 release
Cells were plated in 24-well plates and grown to ~70%
confluency. The medium was replaced and cells were
incubated for 48 hrs, after which time medium was col-
lected, cells were washed two times in Hanks' balanced
salt solution, and cells were lysed in RIPA buffer plus 1%
Triton X-100. Protein content of the cell lysate was deter-
mined by DC protein assay. MCP-1 concentrations in the
conditioned medium were determined using commer-
cially available anti-human (SH-SY5Y or astrocytoma
cells) or anti-mouse (BV-2 cells) MCP-1 ELISA (GE
Healthcare, Piscataway, NJ), and reported as MCP-1 nor-
malized to the protein content of the cell lysate. The
impact of iron loading and iron deprivation on MCP-1
release was determined in each cell line. Each cell line was
treated with varying concentrations of ferric ammonium
citrate (FAC) or desferroxamine (DFO) at levels below
toxic concentrations, determined by MTS cytotoxicity
assay. Additionally, MCP-1 release was determined in
transfected SH-SY5Y cells treated with 50 or 100 μM
Trolox or 25 μM minocycline, all concentrations deter-
mined to be below toxic levels. For FAC, DFO, Trolox, or
minocycline treatment, agents were added to cell culture
medium when medium was changed after cells reached
~70% confluency, resulting in treatment for 48 hours.
Quantitative reverse-transcription polymerase chain 
reaction (qRT-PCR)
We performed qRT-PCR for MCP-1 and GAPDH mRNA
expression in SH-SY5Y cells using PCR primers commer-
cially available from SuperArray. Total RNA was extracted
from five independent cell cultures using the RNeasy Mini
kit (Qiagen) and 5 μg of total RNA was used in a 20 μL
cDNA reaction mixture using the ReactionReady First
Strand cDNA synthesis kit (SuperArray). PCR was per-
formed on cDNA using the RT2 Real-Time SYBR Green
assay (SuperArray) with an ABI 7300 (Applied Biosys-
tems, Foster City, CA) real-time PCR system. The reaction
was initiated at 95°C for 10 min, followed by 40 cycles of
denaturation at 95°C for 15 s, and annealing and exten-
sion at 60°C for 1 min. Expression levels of MCP-1 were
normalized to expression of GAPDH mRNA.
NF- B
Nuclear fractions were isolated from four independent
cultures of each stably-transfected SH-SY5Y cell line using
a nuclear extraction kit (Millipore, Billerica, MA). Nuclear
extracts were analyzed for NF-κB (p50) content by com-
mercially-available colorimetric assay (Cayman Chemi-
cal, Ann Arbor, MI), and results are expressed as optical
density per milligram of nuclear protein.
Statistical analysis
Data are shown as mean ± SEM., with each n representing
an independent cell culture. The data were analyzed by
one-way ANOVA with Tukey's post-hoc analysis or Stu-
dent's  t  test, as appropriate. Differences among means
were considered statistically significant when the p-value
was < 0.05.
Table 1: Cytokines and trophic factors assayed with bead-based immunoassay (Bio-Rad; Hercules, CA)
Eotaxin IL-4 IL-15
fibroblast growth factor (FGF) IL-5 IL-17
granulocyte colony stimulating factor (G-CSF) IL-6 monocyte chemoattractant protein-1 (MCP-1)
granulocyte-macrophage colony stimulating factor (GM-CSF) IL-7 macrophage inflammatory protein-1α (MIP-1α)
interferon-gamma IL-8 MIP-1β
IFN-γ induced protein-10 (IP-10) IL-9 platelet derived growth factor (PDGF) bb
interleukin-1beta (IL-1β) IL-10 regulated on activation normal T-cell expressed and presumably 
secreted (RANTES)
IL-1 receptor antagonist (IL-1ra) IL-12(p70) tumor necrosis factor-alpha (TNF-α)
IL-2 IL-13 vascular endothelial growth factor (VEGF)Journal of Neuroinflammation 2009, 6:6 http://www.jneuroinflammation.com/content/6/1/6
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Results
Stably-transfected SH-SY5Y human neuroblastoma cells
expressing different variants of HFE were generated as pre-
viously reported [1]. Prior to use, cells were differentiated
with 10 μM all-trans retinoic acid to induce a neuronal
phenotype. Expression of FLAG-tagged HFE was con-
firmed in the cells, as shown in Figure 1A. Relative iron
levels were determined in cells using the iron sensitive dye
calcein-AM, whose fluorescence is quenched by binding
iron. The cells transfected with vector alone do not con-
tain HFE and have iron levels similar to the cells carrying
the H63D alleles. Intracellular iron is decreased by the
presence of the Wt HFE, consistent with the known func-
tions of the HFE protein, compared to the vector alone
group as well as the cells carrying the HFE allelic variants.
To determine the effects of HFE polymorphisms, the com-
parisons are limited to the cells expressing HFE and thus
do not include the vector alone transfected cells. The intra-
cellular level of labile iron was affected by the presence of
HFE in these cells in the pattern of C282Y (p < 0.001 vs.
Wt) > H63D (p < 0.05 vs. Wt) > Wt (Figure 1B). These data
demonstrate that the cells in our study had differences in
the labile iron pool associated with the different polymor-
phisms and are generally consistent with our previous
report [6].
The effects of HFE variants on the release of soluble medi-
ators were determined using the transfected SH-SY5Y
cells. A multiplexed antibody-based bead assay was used
to screen a prospective panel of analytes consisting of
inflammatory and anti-inflammatory cytokines and
trophic factors. Eotaxin, IFN-γ, IL-1 receptor antagonist,
IL-7, IL-9, IL-12(p70), IL-13, MCP-1, RANTES, and VEGF
were measured in detectable quantities in cell-condi-
tioned medium from vector-transfected cells or cells
expressing Wt and/or H63D HFE. Of these factors, only
the difference in MCP-1 reached statistical significance
between cells expressing Wt HFE and those expressing
H63D HFE (p < 0.001). Over 48 hours, cells expressing
H63D HFE released 71% more MCP-1 than cells express-
ing Wt HFE (p < 0.001), while cells expressing C282Y
released 42% less MCP-1 than Wt-expressing cells (p <
0.001), as shown in Figure 2A. Similar results were also
obtained using undifferentiated cells (Figure 2B). The
expression of MCP-1 in the H63D and vector-only cells,
like the levels of intracellular iron, was similar.
The mechanism by which HFE variants may differentially
regulate synthesis of MCP-1 was explored at the transcrip-
tion level. RNA was isolated from each SH-SY5Y cell line
for measurement of MCP-1 mRNA expression. After nor-
malizing to the expression of GAPDH mRNA, MCP-1
mRNA expression was 3.0- (p < 0.05), 3.2- (p < 0.05), and
4.1-fold higher (p < 0.01) in vector-transfected, H63D
HFE, and C282Y HFE cells, respectively, compared to cells
expressing Wt HFE (Figure 3A). Between cells expressing
Wt HFE and those expressing H63D HFE or even the vec-
tor alone cells, MCP-1 mRNA expression followed the pat-
MCP-1 secretion in SH-SY5Y cells Figure 2
MCP-1 secretion in SH-SY5Y cells. (A) MCP-1 concentrations were measured in conditioned medium from differentiated 
SH-SY5Y cells and normalized to the protein content of the cell lysis solution and reported here as the average ± SEM of five 
independent assays. Cells expressing H63D HFE released 71% more MCP-1 than cells expressing Wt HFE, while cells express-
ing C282Y HFE released 42% less MCP-1 than Wt-expressing cells. C282Y cells released significantly less MCP-1 than all other 
cell lines. (B) Similar results were obtained using undifferentiated cells. **, and *** represent p < 0.01, and p < 0.001, respec-
tively, compared to Wt HFE cells.
A BJournal of Neuroinflammation 2009, 6:6 http://www.jneuroinflammation.com/content/6/1/6
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tern of MCP-1 secretion. Despite less secretion of MCP-1
associated with the C282Y HFE variant compared to
H63D HFE, however, MCP-1 mRNA expression was not
significantly different between the two cell lines. These
data suggest MCP-1 is regulated at both the transcrip-
tional and post-transcriptional levels and that the mutant
proteins or iron status can affect the regulation.
NF-κB is known to have a prominent role in the transcrip-
tional regulation of many inflammatory mediators
including MCP-1 [16]. Analysis of the nuclear content of
NF-κB in the SH-SY5Y cell lines, however, revealed no dif-
ferences associated with any of the HFE variants (Figure
3B).
Heat stress, likely mediated through induction of heat
shock proteins, reportedly decreases production of MCP-
1 [17]. SH-SY5Y cells were assessed for expression of the
heat shock proteins Hsp70 and Hsp90. Cells expressing
C282Y HFE were characterized by increased expression of
Hsp70 without an increase in Hsp90 expression. Other
cell lines showed no differences in expression of either
protein (Figure 4). H63D HFE and C282Y HFE cells
showed similar levels of MCP-1 mRNA, but significantly
different levels of secreted protein, suggesting that the ele-
vated Hsp70 levels in the C282Y HFE cells may be affect-
ing post-transcriptional or post-translational regulation of
MCP-1.
To directly determine the ability of iron to influence MCP-
1 secretion from cells, each cell line was treated with non-
toxic doses of DFO and FAC to interrogate the effect of cel-
lular iron modulation on MCP-1 release (Figure 5). DFO
treatment resulted in dose-dependent decreased MCP-1
release in vector-transfected (maximum 75%, p < 0.001),
Wt HFE (maximum 68%, p < 0.001), and H63D HFE cells
(maximum 64%, p < 0.001), at 5 μM and 10 μM, but had
no effect in C282Y HFE cells at these concentrations.
Treatment with 90 μM FAC resulted in significantly more
MCP-1 secretion in Wt HFE cells (maximum 76%, p <
0.001), but had no effect at any concentration in other cell
lines. Treatment with either DFO or FAC had no signifi-
MCP-1 mRNA expression and nuclear NF-κB Figure 3
MCP-1 mRNA expression and nuclear NF-κB. (A) RNA was isolated from five separate cultures of differentiated SH-
SY5Y cells and used for quantitative RT-PCR. Expression of MCP-1 mRNA was normalized to the expression of GAPDH 
mRNA. MCP-1 mRNA expression was 3.0-, 3.2-, and 4.1-fold higher in vector-transfected, H63D HFE, and C282Y HFE cells, 
respectively, compared to cells expressing Wt HFE. (B) Nuclear fractions were isolated from four independent cultures of sta-
bly-transfected SH-SY5Y cell lines. Nuclear content of NF-κB (p50) was assessed by colorimetric assay and reported as optical 
density per milligram of nuclear protein. Results are expressed as mean ± SEM. No differences in NF-κB (p50) were found 
between any of the SH-SY5Y cell lines. n = 4. * and ** represent p < 0.05 and p < 0.01, respectively, compared to Wt HFE cells.
A B
Heat shock protein expression Figure 4
Heat shock protein expression. Expression of Hsp70 and 
Hsp90 were determined in differentiated SH-SY5Y cell lines 
by western blotting, demonstrating increased expression of 
Hsp70 in C282Y HFE cells. Samples from three separate cell 
cultures for each cell line were analyzed on the same gel.
Hsp90
Vector Wt  H63D C282Y
Hsp70Journal of Neuroinflammation 2009, 6:6 http://www.jneuroinflammation.com/content/6/1/6
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cant effects in cells expressing C282Y HFE, at these con-
centrations. Higher concentrations of DFO and FAC were
not examined because of data suggesting toxicity at higher
doses of these two agents (data not shown).
In addition to neurons, within the CNS astrocytes and
microglia are also sources of MCP-1 secretion [13]. There-
fore, as an additional model, we utilized two human
astrocytoma cell lines, U251 and U138, to study the effect
of cellular iron status on MCP-1 secretion. Both cell lines
were genotyped for the H63D and C282Y HFE variants
(S.Y. Lee, unpublished). The Wt/Wt HFE U251 cells were
characterized by higher intracellular labile iron levels (p <
0.01) compared to the H63D/Wt HFE U138 cells and had
higher constitutive MCP-1 release (p < 0.001) (Figure 6A).
In order to determine if iron levels were related to the dif-
ferences in MCP-1 secretion, cells were treated with DFO
or FAC. Following treatment with DFO (50 μM), the
secretion of MCP-1 was reduced by 77% (p < 0.001) in
U138 cells (Figure 6B) and by 66% (p < 0.05) in U251
cells (Figure 6C). Iron loading (100 μM FAC) resulted in
a 41% increase of MCP-1 secretion in U138 cells (p <
0.01) with, but this concentration of FAC had no effect in
U251 cells. A doubling of the FAC concentration to 200
Impact of iron on MCP-1 secretion Figure 5
Impact of iron on MCP-1 secretion. Vector-transfected SH-SY5Y cells (A) and SH-SY5Y cells expressing Wt HFE (B), 
H63D HFE (C), or C282Y HFE (D) were treated with 10 μM, 5 μM, or 1 μM desferroxamine (DFO) or 10 μM, 30 μM, or 90 
μM ferric ammonium citrate (FAC) for 48 hours and the secretion of MCP-1 was determined by ELISA and normalized to cel-
lular protein content. n = 4. *, **, and *** indicate p < 0.05, 0.01, and 0.001 compared to control. NS = not significant.
C D
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μM did increase MCP-1 secretion by 107% in U251 cells
(p < 0.001). Thus, regardless of endogenous HFE geno-
type in the astrocytoma cell lines, secretion of MCP-1 was
reduced by similar concentrations of an iron chelator, and
MCP-1 secretion could be induced by iron; the effective
concentration of iron did differ based on HFE genotype.
Additionally, the influence of iron on MCP-1 secretion
was studied in mouse microglial BV-2 cells (Figure 6D).
Iron chelation with 20 μM DFO produced a maximal inhi-
bition of MCP-1 release of 22% (p < 0.01), and treatment
with 100 μM FAC produced a maximal increase in MCP-1
release of 22% (p < 0.05). In both astrocytoma cell mod-
els and the BV-2 cell model, increasing or decreasing cel-
lular iron was directly correlated with MCP-1 release.
The iron chelation and iron addition experiments indicate
that cellular iron status can influence MCP-1 secretion.
Iron status also affects the level of cellular oxidative stress.
Therefore to investigate the possibility that oxidative stress
could be influencing the release of MCP-1, the stably
transfected SH-SY5Y cells were treated for 48 hours with
Trolox, a water-soluble form of vitamin E. Additionally,
MCP-1 secretion in astrocytoma and microglial cells Figure 6
MCP-1 secretion in astrocytoma and microglial cells. Secretion of MCP-1 in U138 (H63D/Wt) and U251 (Wt/Wt) 
human astrocytoma cell lines and mouse microglial BV-2 cells was determined with various concentrations of DFO or FAC, as 
reported in Methods. MCP-1 concentration in medium was determined, relative to the protein content of each well, and was 
normalized to control levels. n = 4. *, **, and *** represent p < 0.05, p < 0.01, and p < 0.001, respectively, compared to con-
trol.Journal of Neuroinflammation 2009, 6:6 http://www.jneuroinflammation.com/content/6/1/6
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cells were treated with minocycline, an antibiotic with
iron chelation, antioxidant, anti-inflammatory, and mito-
chondria-protective properties [18-21], because this drug
has been explored for the treatment of neurodegenerative
diseases. These doses and duration of treatment were cho-
sen based on cell viability assays (data not shown). Trolox
at either concentration had no significant effect on MCP-
1 release in any of the SH-SY5Y cell lines in this study.
Minocycline treatment resulted in a 76% decrease (p <
0.01) and 56% decrease (p < 0.001) in MCP-1 release in
vector-transfected and H63D HFE cells, respectively, but
no significant effects in cells expressing Wt or C282Y HFE
(Figure 7).
Discussion
The analysis of the panel of cytokines and trophic factors
revealed that MCP1 is the most sensitive to cellular iron
status and HFE expression. MCP-1 is known to recruit and
Trolox and minocycline effects on MCP-1 secretion Figure 7
Trolox and minocycline effects on MCP-1 secretion. Stably transfected SH-SY5Y cells were treated for 72 hours with 
Trolox or 48 hours with minocycline to determine the impact of these agents on MCP-1 release. Trolox at either concentra-
tion had no significant effect of MCP-1 release in any of the SH-SY5Y cell lines in this study. Minocycline treatment resulted in 
a 76% decrease (p < 0.01) and 56% decrease (p < 0.001) in MCP-1 release from vector and H63D cells, respectively, but no sig-
nificant effects in Wt or C282Y cells. n = 4. **, and *** indicate p < 0.01, and p < 0.001, respectively, compared to baseline 
MCP-1 secretion for each respective cell line.Journal of Neuroinflammation 2009, 6:6 http://www.jneuroinflammation.com/content/6/1/6
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enhance the activation of cells of the monocyte lineage
[22]. Higher levels of MCP-1 have been found in CSF and
plasma in association with diseases characterized by
excessive inflammation including ALS and AD [23,24]
and in both of these diseases multiple reports exist that
HFE gene variants, particularly the H63D polymorphism,
are risk factors for the disease [1,2,25]. Additionally, pre-
vious studies from our group and others [23,26] have
determined a positive correlation between age and expres-
sion of MCP-1, which may play a role in the higher inci-
dence of neurodegenerative diseases at advanced ages.
Furthermore, Lawless et al. [27] demonstrated that indi-
viduals with hemochromatosis who were homozygous
for the C282Y allele had lower median plasma levels of
MCP-1. Those hemochromatosis patients with at least one
H63D allele, however, had higher median plasma levels
of MCP-1 compared to Wt/Wt  control subjects. These
findings are consistent with the data using neuroblastoma
cells reported herein.
In this study we have utilized a stably-transfected human
neuroblastoma cell culture model to elucidate the conse-
quences of HFE gene variants on MCP-1 expression. There
are two key observations in this study. First is that H63D-
expressing neuroblastoma cells have more iron than Wt
HFE cells and secrete more MCP1. Secondly, the relation-
ship between MCP1 secretion and iron is altered in the
presence of the C282Y HFE variant via a mechanism
which appears to be post-transcriptional or post-transla-
tional. The decreased expression of MCP-1 in the C282Y
HFE cells may be related to the increased expression of
Hsp70 in these cells. Our results on MCP-1 secretion in
the C282Y cells are not consistent with a report using tran-
siently-transfected HEK-293 cells [28]. Our data suggest
that iron could be a driving factor behind the secretion of
MCP-1 and the transient transfection of cells already
expressing Wt HFE may not compare well to our model.
The expression of both Wt and C282Y forms of HFE in a
cell model may have a confounding effect on MCP-1
secretion. It is also possible that the effect on MCP-1 secre-
tion, as shown with the non-transfected astrocytoma cells
in our study, is cell specific.
To determine the effect of cellular iron status on MCP-1
secretion, the cells were treated with either an iron chela-
tor or iron was added to the media. In both the neuroblas-
toma cells and astrocytoma cells, the Wt and H63D cells
and the non-HFE expressing vector control neuroblast-
oma cells, chelating the iron with DFO resulted in a
decrease in MCP-1 expression. Iron chelation failed to
decrease MCP-1 expression in the C282Y HFE cells. The
addition of iron increased MCP-1 expression only in Wt
neuroblastoma cells and both genotypes in the astrocy-
toma cells. Thus in general, it appears that the expression
of MCP-1 can be manipulated by altering iron status.
There is, however, an interaction of genotype and cell type
that influences the MCP-1 expression independent of iron
status. For example, the Wt neuroblastoma cells have less
iron and less MCP-1 expression than the H63D-express-
ing cells. However, the reverse occurs in the astrocytoma
cell lines; the Wt cells have more iron in the labile iron
pool and more MCP-1 expression than the cells carrying
the H63D allele. The astrocytoma cells are heterozygotic
for the H63D variant and thus the baseline differences in
iron status from Wt/Wt and the effect on MCP-1 secretion
may reflect a heterozygotic effect. The astrocytoma cells
also differ in genetic background. In the context of our
study, regardless of cell type and HFE genotype, MCP-1
secretion was increased by increasing cellular iron and
decreased by iron chelation, with the exception of cells
expressing C282Y HFE. Thus it appears that C282Y HFE
has an independent effect on secretion of MCP-1 that
negates the effects of iron.
These data suggest that there is an additional function of
the C282Y HFE mutant protein that is impacting MCP-1
secretion. Effects of the C282Y HFE variant contributing
to the iron overload condition, hereditary hemochroma-
tosis, have been suggested to result from induction of the
ER overload and unfolded protein responses [28]. Subse-
quent effects of these latter responses include activation of
NF-κB [29] and potential activation of apoptosis [30],
which have been associated with overexpression of C282Y
HFE in one cell model [28]. However, we found no differ-
ence in nuclear localization of NF-κB in our cell lines and
have suggested a post-transcriptional or post-translational
effect on MCP-1 that may be directly influenced by the
mutant HFE protein.
The relationship between iron status, HFE status, and
MCP-1 secretion prompted analysis of the known regula-
tory mechanisms for MCP-1 in these cells. MCP-1 is
thought to be regulated mainly at the transcriptional level,
responding to a variety of transcription factors. In neurob-
lastoma cell lines, the presence of the H63D and C282Y
forms of HFE were associated with higher levels of MCP-1
mRNA than in the wildtype cells. The levels of MCP-1
mRNA were similar to that seen in the vector only cells. A
large number of studies have explored the upregulation of
MCP-1 by NF-kB, an oxidative stress-sensitive transcrip-
tion factor which might explain the relationship between
increased iron and MCP-1. However, nuclear localization
of NF-κB did not vary by HFE genotypes, and thus iron
status, in our model, consistent with a previous report that
iron status did not affect baseline nuclear NF-κB in micro-
glial cells [10].
A likely mechanism through which cellular iron status
affects cell stress and MCP-1 regulation is through the for-
mation of reactive oxygen species. In the present study theJournal of Neuroinflammation 2009, 6:6 http://www.jneuroinflammation.com/content/6/1/6
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antioxidant Trolox had no significant effect on MCP-1
secretion in any of the SH-SY5Y cell lines. It is possible
that the length of treatment (72 hours) was not sufficient
to impact MCP-1 synthesis or release; however, longer
duration of treatment showed evidence of cellular toxicity
(data not shown).
An additional pharmaceutical intervention we examined
was minocycline. Minocycline has been explored for use
in treating a number of neuroinflammatory conditions
including ALS, AD, PD, multiple sclerosis, and ischemic
stroke. This compound has iron chelation [18], antioxi-
dant [19], anti-inflammatory [31], caspase-inhibitory
[31], and mitochondria-protective properties [32]. In the
present study, effects of treating cells with minocycline
varied with HFE genotype, significantly decreasing MCP-1
release in the two SH-SY5Y cell lines with the highest
MCP-1 secretion.
The multifaceted nature of minocycline causes uncer-
tainty of the specific contribution of each mechanism of
action. Minocycline, like other tetracyclines, has iron che-
lation properties [18]. The ability to reduce intracellular
iron levels may explain the benefit of minocyline in reduc-
ing MCP-1 secretion in the relatively iron-laden H63D
HFE cells. The lack of effect seen in Wt HFE cells, which
responded to iron chelation with DFO, may result from
other effects of minocycline, or simply reflect the relative
differences in chelator strengths between DFO and mino-
cycline. An alternative explanation for the differential
effects of minocycline involves its actions on mitochon-
dria. Minocycline has been shown to have mitochondrial
protective properties, including reduction of mitochon-
drial swelling and permeability transition pore opening
[32]. Mitochondrial dysfunction in the presence of HFE
gene variants has been suggested for both the C282Y
allelic variant [28] and the H63D HFE variant [6]. Addi-
tionally, we have determined that the H63D HFE variant
is associated with elevated cytosolic calcium levels (man-
uscript under review), that may result from altered mito-
chondrial function. Mitochondrial dysfunction and
elevated calcium levels are mechanisms proposed to
induce transcription of MCP-1; however, the association
of mitochondrial function with MCP-1 regulation is
mostly regulated through NF-κB [33]. Thus, in contrast to
its other actions, the data herein suggest that the effects of
minocycline on MCP-1 secretion involve iron chelation.
Although the exact mechanism of minocycline is not
identified in these cells, these data strongly suggest that
HFE genotype should be considered when assessing treat-
ment efficacy of minocycline, and perhaps other pharma-
cological agents. The lack of benefit of minocycline in the
treatment of humans with ALS, for example [31], despite
its benefit in the mouse model [33], may be due to patient
heterogeneity for HFE alleles. Additional studies of mino-
cycline in patients with ALS may be warranted if they
include stratification by HFE genotype because approxi-
mately 30% of ALS patients carry at least one H63D or
C282Y HFE allele [1,25]. Given the broad effects of HFE
on regulation of MCP-1, such stratification may be justi-
fied in other clinical trials as well.
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